|
DMTK
|
DermTech, Inc.
|
US
|
NASDAQ
|
|
EFTR
|
eFFECTOR Therapeutics, Inc.
|
US
|
NASDAQ
|
|
ELEV
|
Elevation Oncology, Inc.
|
US
|
NASDAQ
|
|
ENOB
|
Enochian Biosciences, Inc.
|
US
|
NASDAQ
|
|
ENZ
|
Enzo Biochem, Inc.
|
US
|
NYSE
|
|
EPIX
|
ESSA Pharma Inc.
|
US
|
NASDAQ
|
|
ERAS
|
Erasca, Inc
|
US
|
NASDAQ
|
|
ERNA
|
Eterna Therapeutics Inc.
|
US
|
NASDAQ
|
|
ERYP
|
Erytech Pharma S.A.
|
US
|
NASDAQ
|
|
EVAX
|
Evaxion Biotech A/S
|
US
|
NASDAQ
|
|
EVLO
|
Evelo Biosciences, Inc.
|
US
|
NASDAQ
|
|
EXAS
|
Exact Sciences Corporation
|
US
|
NASDAQ
|
|
EXEL
|
Exelixis, Inc.
|
US
|
NASDAQ
|
|
FBIO
|
Fortress Biotech, Inc.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
FENC
|
Fennec Pharmaceuticals Inc.
|
US
|
NASDAQ
|
|
FLGT
|
Fulgent Genetics, Inc.
|
US
|
NASDAQ
|
|
FMTX
|
Forma Therapeutics Holdings, Inc.
|
US
|
NASDAQ
|
|
FSTX
|
F-star Therapeutics, Inc.
|
US
|
NASDAQ
|
|
GALT
|
Galectin Therapeutics Inc.
|
US
|
NASDAQ
|